BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15654902)

  • 1. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.
    Breccia M; Carmosino I; Russo E; Morano SG; Latagliata R; Alimena G
    Eur J Haematol; 2005 Feb; 74(2):121-3. PubMed ID: 15654902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
    Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
    Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical management of patients with chronic myeloid leukemia receiving imatinib.
    Deininger MW; O'Brien SG; Ford JM; Druker BJ
    J Clin Oncol; 2003 Apr; 21(8):1637-47. PubMed ID: 12668652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism.
    Vano-Galvan S; Fernandez-Guarino M; Henriquez-Santana A; De Las Heras E; Calbacho M; Jaen P
    Eur J Dermatol; 2007; 17(6):538-9. PubMed ID: 17951138
    [No Abstract]   [Full Text] [Related]  

  • 5. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
    Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
    Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
    Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
    Woo SM; Huh CH; Park KC; Youn SW
    J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
    [No Abstract]   [Full Text] [Related]  

  • 8. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia.
    Deguchi N; Kawamura T; Shimizu A; Kitamura R; Yanagi M; Shibagaki N; Matsue H; Shimada S
    Br J Dermatol; 2006 Jun; 154(6):1216-8. PubMed ID: 16704666
    [No Abstract]   [Full Text] [Related]  

  • 9. Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.
    Breccia M; D'Elia GM; D'Andrea M; Latagliata R; Alimena G
    Eur J Haematol; 2005 Jan; 74(1):89-90. PubMed ID: 15613116
    [No Abstract]   [Full Text] [Related]  

  • 10. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature.
    Kuraishi N; Nagai Y; Hasegawa M; Ishikawa O
    Acta Derm Venereol; 2010; 90(1):73-6. PubMed ID: 20107730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience.
    Bee PC; Gan GG; Teh A; Haris AR
    Med J Malaysia; 2006 Dec; 61(5):547-52. PubMed ID: 17623954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
    Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
    Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
    Breccia M; Cannella L; Frustaci A; Stefanizzi C; Levi A; Alimena G
    Leuk Res; 2008 May; 32(5):835-6. PubMed ID: 17905431
    [No Abstract]   [Full Text] [Related]  

  • 14. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia.
    Kuwano Y; Asahina A; Watanabe R; Fujimoto M; Ihn H; Tamaki K
    Int J Dermatol; 2006 Oct; 45(10):1249-51. PubMed ID: 17040457
    [No Abstract]   [Full Text] [Related]  

  • 15. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
    Thia TJ; Tan HH; Chuah TH; Chow WC; Lui HF
    Singapore Med J; 2008 Mar; 49(3):e86-9. PubMed ID: 18362995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate.
    Simpson E; O'Brien SG; Reilly JT
    Clin Lab Haematol; 2006 Jun; 28(3):215-6. PubMed ID: 16706941
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia.
    Zaucha JM; Wyrowinska E; Prejzner W; Calbecka M; Hellmann A
    Clin Lab Haematol; 2006 Jun; 28(3):208-10. PubMed ID: 16706939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate.
    Cerchione C; Fabbricini R; Pane F; Luciano L
    Leuk Res; 2009 Aug; 33(8):e104-5. PubMed ID: 19232719
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib: a designer drug, another cutaneous complication.
    Dickens E; Lewis F; Bienz N
    Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
    Ayirookuzhi SJ; Ma L; Ramshesh P; Mills G
    Arch Dermatol; 2005 Mar; 141(3):368-70. PubMed ID: 15781678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.